Harrow's IHEEZO Cuts Patient-Reported Discomfort 58% in Intravitreal-Injection Study

MT Newswires Live

Aug 20

Harrow (HROW) said Thursday that IHEEZO reduced patient-reported discomfort by about 58% compared with proparacaine in a prospective study of patients undergoing same-day bilateral intravitreal injections.

The randomized study evaluated 100 eyes from 50 adults, with one eye receiving IHEEZO and the other receiving proparacaine, it said.

IHEEZO produced statistically significant reductions in discomfort at all four measured time points through 24 hours after injection, with the largest differences recorded two minutes and one hour after injection, it added.

The company said the findings could support broader use of IHEEZO among retina specialists, particularly for patients who undergo repeated intravitreal injections over extended periods.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2660289020"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2660289020\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2660289020?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-20 19:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2660289020","market":"us","top_or_hot":-1,"title":"Harrow's IHEEZO Cuts Patient-Reported Discomfort 58% in Intravitreal-Injection Study","media":"MT Newswires Live","content":"<html><body><p> Harrow (HROW) said Thursday that IHEEZO reduced patient-reported discomfort by about 58% compared with proparacaine in a prospective study of patients undergoing same-day bilateral intravitreal injections.</p><p>The randomized study evaluated 100 eyes from 50 adults, with one eye receiving IHEEZO and the other receiving proparacaine, it said.</p><p>IHEEZO produced statistically significant reductions in discomfort at all four measured time points through 24 hours after injection, with the largest differences recorded two minutes and one hour after injection, it added.</p><p>The company said the findings could support broader use of IHEEZO among retina specialists, particularly for patients who undergo repeated intravitreal injections over extended periods.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harrow's IHEEZO Cuts Patient-Reported Discomfort 58% in Intravitreal-Injection Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarrow's IHEEZO Cuts Patient-Reported Discomfort 58% in Intravitreal-Injection Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-20 19:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Harrow (HROW) said Thursday that IHEEZO reduced patient-reported discomfort by about 58% compared with proparacaine in a prospective study of patients undergoing same-day bilateral intravitreal injections.</p><p>The randomized study evaluated 100 eyes from 50 adults, with one eye receiving IHEEZO and the other receiving proparacaine, it said.</p><p>IHEEZO produced statistically significant reductions in discomfort at all four measured time points through 24 hours after injection, with the largest differences recorded two minutes and one hour after injection, it added.</p><p>The company said the findings could support broader use of IHEEZO among retina specialists, particularly for patients who undergo repeated intravitreal injections over extended periods.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4557","symbol_name":"大麻股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2660289020","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2660289020","pubTimestamp":1787226396,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Harrow  said Thursday that IHEEZO reduced patient-reported discomfort by about 58% compared with proparacaine in a prospective study of patients undergoing same-day bilateral intravitreal injections.The randomized study evaluated 100 eyes from 50 adults, with one eye receiving IHEEZO and the other receiving proparacaine, it said.IHEEZO produced statistically significant reductions in discomfort at all four measured time points through 24 hours after injection, with the largest differences recorded two minutes and one hour after injection, it added.The company said the findings could support broader use of IHEEZO among retina specialists, particularly for patients who undergo repeated intravitreal injections over extended periods.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4557":"大麻股","HROW":"Harrow Health Inc","BK4007":"制药"},"translate_title":"在玻璃体内注射研究中，Harrow 的 IHEEZO 将患者报告的不适感减少了 58%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HROW":1},"content_text":"Harrow (HROW) said Thursday that IHEEZO reduced patient-reported discomfort by about 58% compared with proparacaine in a prospective study of patients undergoing same-day bilateral intravitreal injections.The randomized study evaluated 100 eyes from 50 adults, with one eye receiving IHEEZO and the other receiving proparacaine, it said.IHEEZO produced statistically significant reductions in discomfort at all four measured time points through 24 hours after injection, with the largest differences recorded two minutes and one hour after injection, it added.The company said the findings could support broader use of IHEEZO among retina specialists, particularly for patients who undergo repeated intravitreal injections over extended periods.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}